The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Characterization of the Mouse IFN-λ Ligand-Receptor System: IFN-λs Exhibit Antitumor Activity against B16 Melanoma
Abstract
Recently discovered type III IFNs (IFN-λ) exert their antiviral and immunomodulatory activities through a unique receptor complex composed of IFN-λR1 and interleukin-10 receptor 2. To further study type III IFNs, we cloned and characterized mouse IFN-λ ligand-receptor system. We showed that, similar to their human orthologues, mIFN-λ2 and mIFN-λ3 signal through the IFN-λ receptor complex, activate IFN stimulated gene factor 3, and are capable of inducing antiviral protection and MHC class I antigen expression in several cell types including B16 melanoma cells. We then used the murine B16 melanoma model to investigate the potential antitumor activities of IFN-λs. We developed B16 cells constitutively expressing murine IFN-λ2 (B16.IFN-λ2 cells) and evaluated their tumorigenicity in syngeneic C57BL/6 mice. Although constitutive expression of mIFN-λ2 in melanoma cells did not affect their proliferation in vitro, the growth of B16.IFN-λ2 cells, when injected s.c. into mice, was either retarded or completely prevented. We found that rejection of the modified tumor cells correlated with their level of IFN-λ2 expression. We then developed IFN-λ-resistant B16.IFN-λ2 cells (B16.IFN-λ2Res cells) and showed that their tumorigenicity was also highly impaired or completely abolished similar to B16.IFN-λ2 cells, suggesting that IFN-λs engage host mechanisms to inhibit melanoma growth. These in vivo experiments show the antitumor activities of IFN-λs and suggest their strong therapeutic potential. (Cancer Res 2006; 66(8): 4468-77)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37263 · Cited by 2,404
Role of angiogenesis in tumor growth and metastasis
FOLKMAN, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,400
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
Self-citationInterferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., & Stewart, T. A. (1993) · Science · doi:10.1126/science.8456300 · Cited by 1,727
IL-28, IL-29 and their class II cytokine receptor IL-28R
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003) · Nature Immunology · doi:10.1038/ni873 · Cited by 1,570
Cited by
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Sommereyns, C., Paul, S., Staeheli, P., & Michiels, T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000017 · Cited by 772
Marcello, T., Grakoui, A., Barba–Spaeth, G., Machlin, E. S., Kotenko, S. V., Macdonald, M. R., & Rice, C. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.052 · Cited by 561
Self-citationInterferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
Zhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L., & Hartmann, R. (2007) · Journal of Virology · doi:10.1128/jvi.02438-06 · Cited by 479
Metadata
- Authors
- Lasfar, A., Lewis-Antes, A., Smirnov, S. V., Anantha, S., Abushahba, W., Tian, B., Reuhl, K., Dickensheets, H., Sheikh, F., Donnelly, R. P., Raveche, E., & Kotenko, S. V.
- Venue
- Cancer Research
- Published
- 2006-04-15
- Volume
- 66
- Issue
- 8
- Pages
- 4468-4477
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2114860838
- Cited by
- 254
- References
- 39
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of the Mouse IFN-λ Ligand-Receptor System: IFN-λs Exhibit Antitumor Activity against B16 Melanoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-3653
- The paper
- Lasfar, A., Lewis-Antes, A., Smirnov, S. V., Anantha, S., Abushahba, W., Tian, B., Reuhl, K., Dickensheets, H., Sheikh, F., Donnelly, R. P., Raveche, E., & Kotenko, S. V. (2006). Characterization of the Mouse IFN-λ Ligand-Receptor System: IFN-λs Exhibit Antitumor Activity against B16 Melanoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-3653
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.